This is the authors' abstract. We don't add key points for this paper.
The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422). The retention rate was estimated to be 60% after 1 year and 32% after 5 years. Thirty-nine percent (512/1,325) of patients had a seizure reduction of > or =50%, and 13% (183/1,422) became seizure-free for at least 6 months. LEV seems an effective and well tolerated new antiepileptic drug.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Krakow et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: